Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
A drug-eluting stent made from bioresorbable material showed similar mid-term (12 month) safety and efficacy to a metal stent in patients undergoing PCI in the ABSORB Japan study and lays ‘a solid foundation’ for continued evaluation of long term outcomes for bioresorbable stents.
Study presenter Takeshi Kimura from Kyoto University Hospital said: ‘These results support the feasibility of bioresorbable vascular scaffolds to potentially improve longterm outcomes of patients.’
Theoretically, bioresorbable vascular scaffolds (BVS) may provide superior long-term results compared with permanent metallic DES, but whether they are as safe and effective as the metallic DES prior to complete bioresorption has been unknown.
In this ABSORB study, performed between April and December 2013, 400 patients with up to two de novo target lesions were randomised 2:1 to PCI using either BVS (n = 266) or metallic DES (n = 134). The study took place at 38 investigational sites in Japan.
The primary endpoint of target lesion failure (a composite of cardiac death, MI attributable to target vessel, or ischemiadriven target lesion revascularisation at one year) occurred in 4.2% of the BVS patients and 3.8% of the metallic DES patients (RR 1.10; 95% CI 0.39-3.11), demonstrating noninferiority for the bioresorbable stent (P<0.0001). Definite or probable stent scaffold thrombosis at 12 months occurred in 1.5% of patients with both devices. Procedure duration , however, was significantly longer for the bioresorbable stent.
‘These results support the feasibility of BVS use to potentially improve the long-term outcomes of patients undergoing percutaneous coronary intervention,’ write the authors. The study, they add, enrolled a highly selected patient population with mainly stable CAD and single de novo non complex target lesions. ‘As such, the study results should not be generalized to complex lesions, which are often encountered in clinical practice, such as bifurcations, heavily calcified lesions, diffuse disease, and thrombus.’
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved